CORPORATE UPDATE MS MARY HARNEY APPOINTED NON-EXECUTIVE DIRECTOR On 3 September 2024, INOVIQ announced the appointment of Mary Harney as a Non-Executive Director effective 1 October 2024. Ms Harney is an experienced Non-Executive Director and Chief Executive and brings a deep understanding of applied life science research, in addition to experience in biopharmaceutical regulatory affairs and commercialisation. Ms Harney currently serves as Chair of private Australian biotech Oncology One Pty Ltd, a cancer drug discovery company. Ms Harney was previously Chair of Race Oncology (ASX: RAC) and a former Chair of Microbio Limited. DR EMMA BALL APPOINTED CHIEF COMMERCIAL OFFICER On 17 March 2025, INOVIQ announced the appointment of Dr Emma Ball BSc(Hons) PhD MBA GAICD as Chief Commercial Officer (CCO). Dr Ball commenced on 7 April 2025 and is responsible for providing commercial leadership across business development, licensing, marketing and sales to advance the commercialisation of INOVIQ technologies and products. She is an experienced biotechnology commercialisation executive with expertise in business development, licensing, and strategic partnerships across therapeutics, vaccines and diagnostics. Emma is currently Non-Executive Chair of BioMelbourne Network. Most recently, she was Global Head of Ecosystem Development at US-headquartered genomics and precision health leader, Illumina Inc (NASDAQ: ILMN), where she was responsible for strategic partnerships. Previously she held various leadership roles at CSL Limited (ASX: CSL) in business development and licensing, corporate strategy, commercial development and R&D program management. She trained originally as a molecular biologist and has a PhD from the University of Melbourne and an MBA from RMIT University. MEDICAL AND SCIENTIFIC ADVISORY BOARD ESTABLISHED On 10 February 2025, INOVIQ established its Medical and Scientific Advisory Board (MSAB) to provide worldclass research expertise, clinical insight and strategic advice to guide its diagnostic and therapeutic programs. The MSAB comprises internationally renowned clinical researchers and oncologists with expertise in exosome science, diagnostics, clinical trials and cancer treatment of haematological and solid tumours: › Professor H. Miles Prince AM: Leading Clinical Haematologist and Oncologist and Professor at both Melbourne and Monash universities. He is an NHMRC Investigator Fellow and has been principal investigator of over 100 clinical trials including targeted therapeutics (CAR-T therapy) for haematological conditions and cancers. › Professor Phillip K. Darcy: Group Leader of the Cancer Immunotherapy Laboratory at the Peter MacCallum Cancer Centre and NHMRC Principal Research Fellow, focused on novel T cell-based immunotherapy approaches for cancer in preclinical mouse models and clinical translation. › Professor Carlos Salomon: Director of the University of Queensland Centre for Extracellular Vesicle Nanomedicine, Head of the Translational Extracellular Vesicles in Obstetrics and Gynae-Oncology Group and NHMRC Investigator Fellow, specialising in exosome biology and its clinical translation to diagnostics and therapeutics for ovarian cancer and obstetrical syndromes. › Dr James McCracken: Leading Medical Oncologist specialising in breast cancer treatment at Epworth Healthcare and the Peter MacCallum Cancer Centre. His research interests include the field of liquid biopsies for cancer to personalise treatment and minimise toxicity. 2024 CAPITAL RAISE COMPLETION On 5 July 2024, INOVIQ successfully completed its share purchase plan (SPP) with applications totalling $7.293 million, exceeding the $2m target. Allocations to the maximum capacity of A$2.379m were accepted with a pro-rata scale-back. The SPP provided one free quoted option for every two new Shares issued at an exercise price of $1.00 expiring on 8 July 2026. A further $0.25m Director Placement (and 250,000 attaching Placement Options) was approved at an extraordinary general meeting held on 21 August 2024. INVESTOR PROMOTION AND AWARENESS INOVIQ continued to drive awareness of its investment proposition, product pipeline, progress and plans with investors and media through the period. INOVIQ presented at multiple investor conferences and numerous media outlets reported on INOVIQ news, see Presentation tab www.inoviq.com/site/investors/ presentations and Media tab www.inoviq.com/site/ media/inoviq-in-the-news. Review of Operations Directors’ Report Chairman’s Letter CEO’s Report Financial Report Shareholder Information 13 Annual Report 2025
RkJQdWJsaXNoZXIy MjE2NDg3